1stOncology™: Cancer Intelligence Service – Page 7370 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

HUTCHMED to Announce 2021 Final Results

On February 7, 2022 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) reported that its final results for the year ended December 31, 2021 on Thursday, March 3, 2022 at 7:00 am Eastern Standard Time (EST) / 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT) (Press release, Hutchison China MediTech, FEB 7, 2022, View Source [SID1234607781]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.

The conference call and audio webcast will take place at 8:00 am EST / 1:00 pm GMT / 9:00 pm HKT on Thursday, March 3, 2022 and will be webcast live via the company website at www.hutch-med.com/event/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

Kyowa Kirin Announces Changes to Its Organization

On February 7, 2022 Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto, "Kyowa Kirin", TSE: 4151) reported that it will make changes to its organization as of April 1, 2022 (Press release, Kyowa Hakko Kirin, FEB 7, 2022, View Source [SID1234607780]).

Outline of the changes:
1) The Strategy Division will be newly established.
2) The Corporate Strategy & Planning Department will be split into the Corporate Strategy Department and the Corporate Planning Department, and both departments will be placed in the Strategy Division.
3) The name of the Overseas Business Planning Department will be changed to the Overseas Business Strategy Department, which will be placed in the Strategy Division.
4) The Established Medicine Strategy Department will be newly established and placed in the Strategy Division.

Purpose of the organization changes:
1) Given the development of the business of Kyowa Kirin including its globalization, in addition to consolidating and coordinating each business and product strategy department, to establish a structure to supervise non-financial topics and established medicines as well.
2) To systematically position the functions of supervising its mid-and long-term corporate strategy and managing its corporate plan.
3) To strengthen overseas business strategies and strategic management of regional headquarters.
4) To develop and execute product strategies closely coordinated with business management.
5) To comprehensively grasp the status of established medicines that Kyowa Kirin owns and to supervise business execution to ensure that it proceeds efficiently.

Announcement of Consolidated Financial Results Fiscal 2021

On February 7, 2022 Kyowa Hakko Kirin reported that Consolidated Financial Summary (IFRS)Fiscal 2021 (Press release, Kyowa Hakko Kirin, FEB 7, 2022, View Source [SID1234607779])

1. Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 (from January 1, 2021 to December 31, 2021)

(1) Consolidated operating results
(2) Consolidated financial position
(3) Consolidated cash flows

2. Dividends

3. Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2022 (from January 1, 2022 to December 31, 2022) Non-Consolidated Results for the Fiscal Year Ended December 31, 2021 (Japanese GAAP) (from January 1, 2021 to December 31, 2021)
(1) Non-consolidated operating results
(2) Non-consolidated financial position

These financial results reports are exempt from audit conducted by certified public accountants or an audit corporation.

* Notice regarding the appropriate use of the earnings forecasts and other special comments
The forward-looking statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.

For more information regarding our suppositions that form the assumptions for the earnings forecasts, please see pages 17 and 18 of the attachment, "(5) Outlook for Fiscal 2022" in "
1. Summary of Business Performance and Financial Position."

Notice Regarding Recording of Extraordinary Income in Non-consolidated Finacial Statements

On February 7, 2022 Kyowa Kirin Co., Ltd. (hereinafter, the "Company") reported that it has recorded extraordinary income in the non-consolidated financial statements for Fiscal 2021 (January 1, 2021 to December 31, 2021) (Press release, Kyowa Hakko Kirin, FEB 7, 2022, View Source [SID1234607778]). The details are as follows.

1. Details of extraordinary income The Company had provided an allowance for doubtful accounts for bonds issued by FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., which is an associate accounted for using the equity method of the Company, that the Company had underwritten. However, given the fact that the bonds have started to be repaid and in consideration of the repayment schedule going forward, etc., the Company recorded extraordinary income of ¥29,834 million as reversal of allowance for doubtful accounts for subsidiaries and associates in the non-consolidated financial statements for the fiscal year ended December 31, 2021.

2. Impact on consolidated financial results Because the reversal of allowance for doubtful accounts for subsidiaries and associates was eliminated in the consolidated financial statements, there is no impact on the consolidated financial results.

Invitation to Presentation of Herantis Pharma’s 2H and Full Year Report 2021

On February 7, 2022 Herantis Pharma Plc ("Herantis"), developing disease modifying therapies for Parkinson’s disease, reported that the company will report 2H and Full Year report 2021 and hold a live webinar (in English) for investors, analysts and media on (Press release, Herantis Pharma, FEB 7, 2022, View Source,c3499761 [SID1234607777]):

Thursday, March 3rd, 2022, at 10:00 EET / 9:00 CET.

Herantis will publish the company’s 2H and Full Year 2021 report on March 3, 2022, at 8:00 EET /7:00 CET.

The management will present Herantis and comment on the 2H and Full Year 2021 Report followed by a live Q&A session. Please join the webinar a few minutes in advance.